Porcine D-type coronavirus S protein and recombinant adenovirus

By designing and expressing the recombinant adenovirus of the S protein of Porcine D-type coronavirus, the problem of lack of specific vaccines is solved, and effective prevention and control of PDCoV is achieved, and clinical application potential is available.

CN118994418AActive Publication Date: 2024-11-22SICHUAN HUASHEN ANIMAL BIOLOGICAL PRODS

Patent Information

Application Number
CN202411177263.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-22
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

There are currently no specific drugs and vaccines that can be used to prevent and control pig D-CoV infection, causing severe epidemics and high mortality rates in pig herds.

Method used

A pig D-type coronavirus S protein was designed to construct a recombinant adenovirus vector by inserting specific signal peptides and tags into its sequence and codon optimization, expressing and secreting the protein to induce specific immunity in animals.

Benefits of technology

This method can effectively induce specific immunity in immunized animals, provide scientific and technical means for the prevention and control of PDCoV, and has potential clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994418A_ABST
    Figure CN118994418A_ABST
Patent Text Reader

Abstract

The invention discloses a porcine D-type coronavirus S protein and a recombinant adenovirus, and the porcine D-type coronavirus S protein expressed by a live vector vaccine has the following characteristics: on the basis of a PDCoV SC strain S protein sequence, an MDAMKRGLCCVLLLCGAVFVSN TPA secretion signal peptide sequence is inserted into an N segment, a GSGYIPEAPRDGQAYVRKDGEWVLLSTFGSGHHHHHH tag is inserted into a C end, and after S1 and S2 cleavage sites are mutated into GGSGGGGSGGGS, sequence optimization is carried out according to the characteristics of a Sus Scrofa codon. The vaccine constructed by the invention can effectively induce immune animals to generate specific immunity, and is applied to clinical application to provide a scientific technical means for prevention and control of PDCoV.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of vaccine preparation, and in particular to a swine delta coronavirus S protein and a recombinant adenovirus expressing the protein. Background Art

[0002] Porcine deltacoronavirus (PDCoV) is a highly contagious porcine enteric coronavirus characterized by watery diarrhea, acute diarrhea, and high incidence of young suckling piglets in infected pigs, and has been reported in breeding areas across the country. Fecal-oral infection is the main route of transmission of PDCoV, and feces and vomitus and other contaminants are the main transmission channels of the virus. In diarrheal groups, viral RNA persists for 19-28 days in the intestine and up to 42 days in oral secretions.

[0003] Clinical symptoms such as diarrhea and vomiting after oral administration of PDCoV in 5-21-day-old newborn piglets or regular piglets appear 1-3 days after infection. PDCoV replication is limited to the epithelial cells of the small intestine and large intestine, and infection can lead to atrophy and acute necrosis of the small intestinal villi. In the acute phase of infection, PDCoV antigens are mainly present in the atrophic middle jejunum, and in small amounts in the duodenum, proximal jejunum, and cecum. Occasionally, it is present in the crypt epithelial cells, lamina propria, Peyer's patches, and mesenteric lymph nodes of the jejunum and ileum.

[0004] Seronegative pigs of all ages are susceptible to PDCoV. In seronegative breeding farms, the incidence rate of piglets can be as high as 100%. Some breeding farms in the United States have reported mortality rates as high as 40%. PDCoV outbreaks in breeding farms in China and Thailand in Asia can cause the death of 64%-80% of suckling piglets.

[0005] There are currently no specific drugs and vaccines available, so the development of a safe and effective PDCoV vaccine is of great significance for the clinical prevention and control of the disease. Summary of the invention

[0006] The purpose of the present invention is to provide a porcine delta coronavirus S protein and a recombinant adenovirus, which can effectively induce immune animals to produce specific immunity and are expected to be used in clinical practice to provide scientific technical means for the prevention and control of PDCoV.

[0007] In order to solve the above technical problems, the technical solution adopted by the present invention is: Design a swine delta coronavirus S protein, the specific method is as follows: Based on the S protein sequence of PDCoV SC strain, the MDAMKRGLCCVLLLCGAVFVSNTPA secretion signal peptide sequence was inserted into the N segment, the YIPEAPRDGQAYVRKDGEWVLLSTFGSGHHHHHH tag was inserted into the C-terminus, and the S1 and S2 cleavage sites were mutated to GGSGGGGSGGGS. After sequence optimization according to the characteristics of Sus Scrofa codons, it was synthesized and directionally inserted into the EcoRⅠ and HindⅢ restriction sites of the pDC316-mCMV-EGFP vector. The constructed vector was named pDC316-PDCoV-S.

[0008] Wherein, the amino acid sequence is shown as SEQ ID NO.1.

[0009] Wherein, the nucleotide sequence is shown as SEQ ID NO.2.

[0010] Furthermore, the sequence was optimized according to the characteristics of Sus Scrofa codons and then synthesized and directionally inserted between the EcoRⅠ and HindⅢ restriction sites of the pDC316-mCMV-EGFP vector.

[0011] Furthermore, the pDC316-PDCoV-S vector was co-transfected with pBHGloxdelE13cre into 293A cells to obtain a recombinant adenovirus expressing the S protein of swine delta coronavirus.

[0012] Compared with the prior art, the present invention has the following beneficial effects: The PDCoV S protein skeleton expressed by the present invention is the SC strain S protein, but the MDAMKRGLCCVLLLCGAVFVSN secretion signal peptide sequence is inserted into its N segment, the YIPEAPRDGQAYVRKDGEWVLLSTFGSGHHHHHH tag is inserted into the C-terminus, and the S1 and S2 cleavage sites are mutated to GGSGGGGSGGGS, thereby obtaining a sequence that can secrete and express the S fusion protein, and synthesizing and inserting it directionally into the EcoRⅠ and HindⅢ restriction sites of the pDC316-mCMV-EGFP vector after sequence optimization according to the characteristics of the Sus Scrofa codon, thereby obtaining a recombinant vector expressing the PDCoV S protein, and further using the vector to prepare a recombinant adenovirus expressing the PDCoV S protein. The recombinant adenovirus constructed by the present invention can effectively induce the immune animal to produce specific immunity, and is expected to be used in clinical practice, providing scientific technical means for the prevention and control of PDCoV. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0014] Figure 1 This is a cytopathic effect diagram of the rADV-DS strain of the present invention. DETAILED DESCRIPTION

[0015] In the following, only some exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the embodiments of the present invention. Therefore, the drawings and descriptions are considered to be exemplary and non-restrictive in nature. Embodiments of the present invention are described in detail below in conjunction with the accompanying drawings.

[0016] Embodiment 1 This example discloses a recombinant adenovirus expressing the S protein of swine delta coronavirus, the characteristics of the S protein are as follows: Using the S protein sequence of PDCoV SC strain as the backbone, the MDAMKRGLCCVLLLCGAVFVSNTPA secretion signal peptide sequence was inserted into the N segment, the YIPEAPRDGQAYVRKDGEWVLLSTFGSGHHHHHH tag was inserted into the C-terminus, the middle S1 and S2 cleavage sites were mutated to GGSGGGGSGGGS, and the sequence was optimized according to the characteristics of Sus Scrofa codons and then synthesized and directionally inserted into the EcoRⅠ and HindⅢ restriction sites of the pDC316-mCMV-EGFP vector. The constructed vector was named pDC316-PDCoV-S.

[0017] Among them, the amino acid sequence expressed by the S protein is shown in SEQ ID NO.1.

[0018] SEQ ID NO.1: MDAMKRGLCCVLLLCGAVFVSNQRALLIMTLLCLVRAKFADDLLDLLTFPGAHRFLHKPTSNSTSLHSRANNFDVGVLPGYPTKNVNLFSPLTNSTLPINGLHRSYQPLMLNCLTKITNHTLSMYLLPSEIQTYSCGGAMVKYQTHDAVRIILDLIATDHISVEVVGQHGENYVFVCSEQFNDTTALHKSTFFSLNSALYCFINNTYLGILPPDLTDFTVYRTGQFYANGYLLGTLPITVNYVRLYRGHLPANSAHFALANLTDTLITLTNTTISQITYCDKSVVDSIACQRSSHEVEDGFYSDPKSAVRARQRTIVTLPKLPELEVVQLNISAHMDFGEARLDSVTINGNTSYCVTKPYFRLETNFMCTGCTMNLRTDTCSFDLSAVNNGMSFSQFCLSTESGACEMKIIVTYVWKYLLRQRLYVTAVEGQTHTGTTSVHATDTSSVITDVCTDYTIYGVSGTGIIKPSDLLLHNGIAFTSPTGELYAFKDITTGKTLQVLPCETPSQLIVINNTVVGAITSSNSTENNRFTTTIVTPTFFYSTNATTFNCTKPVLSYGPIS GGSGGGGSGGGSGEVEIPSAFSLSVQTEYLQVQAEQVIVDCPQYVCNGNSRCLQLLAQYTSACSNIEAALHSSAQLDSREIINMFQTSTQSLQLANITNFKGDYNFSSILTTRLGGRSAIEDLLFNKVVTSGLGTVDQDYKACSRDMAIADLVCSQYYNGIMVLPGVVDAEKMAMYTGSLTGAMVFGGLTAAAAIPFATAVQARLNYVALQTNVLQENQKILAESFNQAVGNISLALSSVNYAIQQTSEALNTVAIAIKKIQTVVNQQGEALSHLTAQLSNNFQAISTSIQDIYNRLEEVEANQHVDRLITGRLAALNAYVTQLLNKMSQIRQSRLLAQQKINECVKSQSSRYGFCGNGTHIFSLTQTAPNGIFFMHAVLVPNKFTRVNASAGICVDNTRGYSLQPQLILYQFNNSWRVTPRNMYEPRLPRQADFIQLTDCSVTFYNTTAANLPNIIPDVIDVNQGSG YIPEAPRDGQAYVRKDGEWVLLSTF GSGHHHHHH。

[0019] Furthermore, the nucleotide sequence is as shown in SEQ ID NO.2.

[0020] SEQ ID NO.2:

[0021] In order to facilitate those skilled in the art to further understand the present invention, the present application is further explained below with reference to specific cases.

[0022] 1. Construction of recombinant adenovirus vaccine expressing PDCoV S protein: 1.1 Construction of recombinant adenovirus vector: Based on the S protein sequence of PDCoV SC strain, the MDAMKRGLCCVLLLCGAVFVSNTPA secretion signal peptide sequence was inserted into the N segment and the C-terminal YIPEAPRDGQAYVRKDGEWVLLSTF GSGHHHHHH tag, the middle S1 and S2 cleavage sites were mutated to GGSGGGGSGGGS, and then the sequence was optimized according to the characteristics of Sus Scrofa codons and synthesized by Nanjing GenScript Biotechnology Co., Ltd. and inserted into the EcoRⅠ and HindⅢ restriction sites of the pDC316-mCMV-EGFP vector. The constructed vector was named pDC316-PDCoV-S; The amino acid sequence designed by the present invention is shown in SEQ ID NO.1, and the corresponding nucleotide sequence is shown in SEQ ID NO.2.

[0023] 1.2 Small-scale preparation and purification of recombinant adenovirus rADV-DS strain: 293A cells were subcultured to 12-well plates according to the conventional method. When the cell confluence was about 50%, pDC316-PDCoV-S plasmid and pBHGloxdelE13cre plasmid were transfected using transfection reagent (FuGENE® HD, Promega). 6ul of transfection reagent and 1ug of pDC316-PDCoV-S plasmid and pBHGloxdelE13cre plasmid were used. After transfection, the cells were cultured in a 37°C, 5% carbon dioxide incubator. The cell status was observed daily. Five days after transfection, lesions were observed, such as Figure 1 As shown, the number of pathological cells increased after continued culture for 48 hours, and the cells were repeatedly frozen and thawed three times at -80°C, centrifuged at 12000 rpm, and stored at -80°C, which was counted as the P1 generation virus of the rADVDS strain. Figure 1 In the middle, from left to right, the CPE lesions of control cells, 5 days and 7 days after transfection are shown.

[0024] According to the conventional method, 293A cells were subcultured into 96-well plates, and rADV DS strain P1 virus stored at -80°C was diluted 10-fold using serum-free DMEM cell culture medium. 1 ~10 8The dilution was inoculated in the culture wells with 293A cell suspension, and 100ul virus dilution was added to each well, with 24 wells for each dilution gradient. After adding the virus dilution, the cells were cultured in a 37°C, 5% carbon dioxide incubator and observed daily. When the lowest dilution showed a single plaque, the virus solution in the well was inoculated with 293A for expansion culture. When the cell lesion rate reached 80%, the virus was harvested, and the cells were repeatedly frozen and thawed at -80°C, centrifuged at 12000rpm for 5 minutes, and the supernatant was aliquoted and stored at -80°C, which was recorded as the rADV DS strain P3 virus.

[0025] The rADV DS strain P3 virus was inoculated into 293A cells according to conventional methods and continued to be cultured and expanded to the rADV DS strain P5 virus. All harvested viruses were stored at -80°C.

[0026] 293A cells were subcultured to T175 cell flasks according to the conventional method. After the cells grew into a dense monolayer, the cell culture medium was removed, 0.5 ml of rADV DS strain P3 virus was inoculated, and adsorbed in a 37°C cell culture incubator for 60 minutes. Then 30 ml of 2% calf serum DMEM culture medium was added to the inoculated cell flask. Culture was carried out in a 37°C, 5% carbon dioxide incubator. After more than 90% of the cells showed cytopathic effects, the virus solution was harvested, centrifuged at 12000 rpm for 10 minutes, the supernatant was added to a 100KD ultrafiltration centrifuge tube (purchased from MERCK), centrifuged at 5000 rpm to 1 / 10 of the original volume, 0.1 M phosphate buffer was added to the original volume, centrifuged at 5000 rpm to 1 / 100 of the original volume, and finally glycerol was added at a ratio of 5:1, and the tubes were aliquoted and stored at -80°C.

[0027] 293A cells were subcultured into 96-well plates according to conventional methods and cultured in a 37°C, 5% carbon dioxide incubator. The rADVDS strain P4, P5 virus and purified virus were diluted 10-fold to 10 using 2% serum DMEM. 12 , inoculate 293A cells after dilution, and inoculate 8 wells for each dilution. After inoculation, culture in a 37°C, 5% carbon dioxide incubator for 6 days. Place the cultured 96-well plate under an inverted fluorescence microscope to observe whether each dilution well has cytopathic effect, record the number of cytopathic wells for each dilution, and calculate the TCID of rADV DS strain P4, P5 and purified virus according to the Reed-Muench method 50 10 respectively 7.5 TCID 50 / ml, 10 9 TCID 50 / ml, 10 11 TCID 50 / ml.

[0028] 1.3 Determination of humoral immune effect of rADV-DS strain in mice: Twenty-four 6-8 week old SPF grade Kunming mice were purchased (Chengdu Dashuo Biotechnology Co., Ltd.) and randomly divided into four groups. The purified rADV DS strain virus was diluted with serum-free DMEM and then injected 10 times 6 , 10 7 , 10 8 TCID 50 The rADV PS strain virus was injected into the leg muscle with an injection volume of 100ul. Serum was collected before immunization, 2 weeks after immunization, and 4 weeks after immunization to determine specific antibodies.

[0029] The PDCoV S protein peptide FYSDPKSAV was used, and a cysteine ​​residue was added to the C-terminus for BSA coupling. The peptide was synthesized and labeled with BSA protein by Nanjing GenScript Biotechnology Co., Ltd. The synthesized and BSA-coupled peptide (purity 99%) was taken and dissolved to 1 mg / ml with sterile water for injection, and then diluted to 4 ug / ml with 0.05M pH 9.6 carbonate buffer. Take the ELISA plate, add 100ul of diluted peptide solution to each well, and coat at 2-8℃ for 12-16 hours; remove the peptide-containing coating solution, add 0.1ml blocking solution (0.15M PBS, 0.05% Tween 20, 3% BSA, pH 7.4) to each well, and block at 37℃ for 3h; remove the blocking solution and wash 5 times with PBST (0.15M PBS, 0.05% Tween 20, pH 7.4); dilute the collected serum 100 times, add 100ul of diluted serum to each well, set up the dilution control well and incubate at room temperature for 60min; remove the serum and wash 5 times with PBST; add 100ul of 1:5000 diluted HRP-labeled rabbit anti-mouse secondary antibody (purchased from Sangon Biotech (Shanghai) Co., Ltd.) to each well, incubate at room temperature for 30min, and wash 5 times with PBST; add 100ul of TMB colorimetric solution, incubate at room temperature for 15min, add 50ul The reaction was terminated with 2M sulfuric acid, and the OD450 light absorption value was measured. The test wells and negative control wells with A450nm>2.1 were judged as positive. The antibody test results after immunization with rADV DS strain are shown in Table 1.

[0030] Table 1 shows the results of antibody determination after immunization with rADV DS strain As shown in Table 1, the antibodies in the immunized groups were all positive, and the rADV DS strain 10 8 TCID50 group higher than 10 7 TCID 50The rADV DS strain can induce specific humoral immune responses in mice. The present invention can effectively induce specific immunity in immune animals and is expected to be used in clinical practice to provide scientific technical means for the prevention and control of PDCoV.

[0031] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0032] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A swine delta coronavirus S protein, It is characterized in that The swine delta coronavirus S protein has the following characteristics: Based on the S protein sequence of the PDCoV SC strain, the MDAMKRGLCCVLLLCGAVFVSNTPA secretion signal peptide sequence was inserted into the N segment, the YIPEAPRDGQAYVRKDGEWVLLSTFGSGHHHHHH tag was inserted into the C-terminus, and the S1 and S2 cleavage sites were mutated to GGSGGGGSGGGS. Then, the sequence was optimized according to the characteristics of Sus Scrofa codons. The amino acid sequence of the S protein expressed is shown in SEQ ID NO.

1.

2. A swine delta coronavirus S protein according to claim 1, Features: The nucleotide sequence of the S protein of swine delta coronavirus is shown in SEQ ID NO.

2.

3. A recombinant adenovirus expressing the S protein of swine delta coronavirus, Features: Contains the nucleotide sequence of the swine delta coronavirus S protein as described in claim 2.

4. A vaccine, Features: The recombinant adenovirus expressing the S protein of swine delta coronavirus as described in claim 3 is prepared.

Citation Information

Patent Citations

  • Porcine coronavirus vaccines

    CN110545841A

  • Porcine delta coronavirus strain and application thereof

    CN113493775A

  • S protein gene and application thereof in porcine delta coronavirus vaccine

    CN114317564A

  • Porcine epidemic diarrhea virus S protein mutant as well as preparation method and application thereof

    CN116284453A

  • Recombinant adenovirus vector containing porcine deltacoronavirus immune protein, strain, vaccine and application

    CN116676341A

Cited By

  • Porcine delta coronavirus S1 protein nanoparticle vaccine CTDnps and application thereof

    CN121041421A

  • A porcine deltacoronavirus S1 protein nanoparticle vaccine CTDnps and its application

    CN121041421B